Deals

Bayer Warns on Profit Outlook After $63 Billion Monsanto Deal

Delayed closing will hurt results for this year, company says
Bayer sees 8,700 people seeking damages on Roundup herbicide

CEO Werner Baumann says the Monsanto business is "very healthy."(Source: Bloomberg)

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Naomi Kresge and Tim Loh

September 5, 2018 at 5:53 AM UTC

Updated on

September 5, 2018 at 8:56 AM UTC

This article is for subscribers only.

Bayer AG’s $63 billion Monsanto purchase has suffered regulatory delays, mounting legal claims and now will yield lower earnings for the year than earlier forecast. Still, the company’s CEO says he has “no regrets.”

The German company lost out on revenue from Monsanto’s busy spring season, when farmers in the Northern Hemisphere plant the bulk of their crops, because antitrust challenges slowed the acquisition of the maker of Roundup weed killer. The shares fell as much as 3.7 percent in Frankfurt, and have lost about 23 percent this year.